NeoGenomics NEO has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below offers a condensed view of their recent ...
StockStory.org on MSN
A look back at testing & diagnostics services stocks’ Q1 earnings: NeoGenomics (NASDAQ:NEO) vs the rest of the pack
Looking back on testing & diagnostics services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, ...
The big shareholder groups in NeoGenomics Inc (NASDAQ:NEO) have power over the company. Institutions often own shares in more established companies, while it’s not unusual to see insiders own a fair ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
NeoGenomics (NEO) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings ...
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting results this Tuesday after market close. Here’s what investors should know. NeoGenomics beat analysts’ revenue ...
NeoGenomics is transitioning from a commodity diagnostic provider to a comprehensive precision oncology platform, leveraging deep relationships with community oncologists. NEO’s clinical services ...
NeoGenomics (NEO) shares ended the last trading session 7.2% higher at $11.13. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated ...
Good morning ladies and gentlemen. Thank you for standing by. Welcome to the NeoGenomics First Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. After the ...
Ratings for NeoGenomics (NASDAQ:NEO) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results